Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Ideaya Biosciences Inc (IDYA)

Ideaya Biosciences Inc (IDYA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,009,386
  • Shares Outstanding, K 87,814
  • Annual Sales, $ 218,710 K
  • Annual Income, $ -113,700 K
  • EBIT $ -159 M
  • EBITDA $ -165 M
  • 60-Month Beta 0.09
  • Price/Sales 13.97
  • Price/Cash Flow N/A
  • Price/Book 2.98

Options Overview Details

View History
  • Implied Volatility 179.01% (+0.15%)
  • Historical Volatility 46.23%
  • IV Percentile 100%
  • IV Rank 100.00%
  • IV High 179.01% on 03/18/26
  • IV Low 51.87% on 07/21/25
  • Expected Move (DTE 2) 3.27 (9.72%)
  • Put/Call Vol Ratio 0.13
  • Today's Volume 26
  • Volume Avg (30-Day) 887
  • Put/Call OI Ratio 1.04
  • Today's Open Interest 30,541
  • Open Int (30-Day) 22,497
  • Expected Range 30.40 to 36.94

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 19 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate -1.06
  • Number of Estimates 4
  • High Estimate -0.94
  • Low Estimate -1.17
  • Prior Year -0.82
  • Growth Rate Est. (year over year) -29.27%

Price Performance

See More
Period Period Low Period High Performance
1-Month
30.81 +8.60%
on 02/19/26
35.68 -6.22%
on 03/03/26
+2.54 (+8.21%)
since 02/18/26
3-Month
29.47 +13.55%
on 02/17/26
39.28 -14.82%
on 01/07/26
+0.20 (+0.60%)
since 12/18/25
52-Week
13.45 +148.77%
on 04/09/25
39.28 -14.82%
on 01/07/26
+14.99 (+81.16%)
since 03/18/25

Most Recent Stories

More News
IDEAYA Biosciences Announces Upcoming Presentations at AACR 2026 Highlighting Multiple Clinical Stage Pipeline Programs

SOUTH SAN FRANCISCO, Calif. , March 18, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a leading precision medicine oncology company, today announced the publication of abstracts for...

IDYA : 33.35 (-2.68%)
IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE892, a Potential Best-In-Class PRMT5 Inhibitor for MTAP-Deleted Solid Tumors, and Provides MTAP and CDKN2A Pipeline Update

SOUTH SAN FRANCISCO, Calif. , March 9, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a leading precision medicine oncology company, today announced that the first patient has been...

IDYA : 33.35 (-2.68%)
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif. , Feb. 27, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics,...

IDYA : 33.35 (-2.68%)
IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE034, a Potential First-In-Class B7H3/PTK7 Bispecific TOP1 ADC

SOUTH SAN FRANCISCO, Calif. , Feb. 25, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a leading precision medicine oncology company, today announced that the first patient has been...

IDYA : 33.35 (-2.68%)
IDEAYA Biosciences Announces Appointment of Dr. Theodora (Theo) Ross, M.D., Ph.D., as Chief Development Officer

SOUTH SAN FRANCISCO, Calif. , Feb. 23, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a leading precision medicine oncology company, today announced the appointment of Dr. Theodora...

IDYA : 33.35 (-2.68%)
IDEAYA Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update

SOUTH SAN FRANCISCO, Calif. , Feb. 17, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a leading precision medicine oncology company, provided a business update and announced financial...

IDYA : 33.35 (-2.68%)
IDEAYA Biosciences to Participate in Upcoming February 2026 Investor Relations Events

SOUTH SAN FRANCISCO, Calif. , Feb. 2, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics,...

IDYA : 33.35 (-2.68%)
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif. , Jan. 30, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics,...

IDYA : 33.35 (-2.68%)
IDEAYA Biosciences Provides a Business Update and Outlines 2026 Corporate Objectives at the 44th Annual J.P. Morgan Healthcare Conference

SOUTH SAN FRANCISCO, Calif. , Jan. 11, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a leading precision medicine oncology company, provided a business update including an overview...

IDYA : 33.35 (-2.68%)
Targeted Precision: Rare Disease Assets Attract Record Regulatory Momentum

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – Baystreet.ca News Commentary – Genomics-driven cancer diagnostics are accelerating market growth, with the genomics in cancer care market...

ONCY : 0.9749 (-1.60%)
IDYA : 33.35 (-2.68%)
ZLAB : 18.81 (-1.10%)
CHRS : 1.5900 (-5.36%)
HALO : 63.48 (-2.53%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

IDEAYA Biosciences Inc. is an oncology-focused precision medicine company. It focuses on the discovery and development of therapeutics for patients using molecular diagnostics. The company's product pipeline consists of IDE196, MAT2A, PARG, Pol-theta and WRN which are in clinical stage. IDEAYA Biosciences...

See More

Key Turning Points

3rd Resistance Point 35.93
2nd Resistance Point 35.60
1st Resistance Point 34.93
Last Price 33.35
1st Support Level 33.94
2nd Support Level 33.61
3rd Support Level 32.94

See More

52-Week High 39.28
Last Price 33.35
Fibonacci 61.8% 29.41
Fibonacci 50% 26.36
Fibonacci 38.2% 23.32
52-Week Low 13.45

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar